Daridorexant for Alzheimer Disease Prevention

Inclusion Criteria: * Without dementia as determined by: MoCA \>21 or MMSE \> 24 or Clinical Dementia Rating \<1 * Minimum of 6 years of formal education * Stable psychoactive medication for 1 month prior to screening with no intention to change dose during treatment period * Capacity to provide written consent in English or French Exclusion Criteria: * Clinical diagnosis of major neurocognitive disorder * Unstable psychiatric condition: * Clinically significant active suicidal ideations * Unstable medical condition in the opinion of the investigator. * Known or suspected history of drug or alcohol dependence or abuse within one year of the screening visit * Currently taking a DORA * Allergy or significant adverse reaction to DORA * Use of benzodiazepines or z-drugs \> 2 times per week in the last month. * Use of major and moderate CYP3A4 inducers and inhibitors * Use of strong central nervous system depressants, opioids, strong analgesics, antipsychotics, sedative antidepressants. * Active use of cholinesterase inhibitors or memantine * Women who are breast feeding or pregnant * Severe obstructive sleep apnea (OSA)\* * Clinically significant non-treated rapid eye movement (REM) sleep behavior disorder, restless leg syndrome or parasomnia; * Diagnosis of narcolepsy